Search

Your search keyword '"Mattour, Ahmad H."' showing total 5 results
Start Over Author "Mattour, Ahmad H."
5 results on '"Mattour, Ahmad H."'

2. The Combination of Navitoclax and Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Mediates Responses Suggestive of Disease Modification

Author

Passamonti, Francesco, primary, Foran, James M., additional, Tandra, Anand, additional, De Stefano, Valerio, additional, Fox, Maria Laura, additional, Mattour, Ahmad H., additional, McMullin, Mary Frances, additional, Perkins, Andrew Charles, additional, Rodríguez-Macias, Gabriela, additional, Sibai, Hassan, additional, Qin, Qin, additional, Sun, Yan, additional, Potluri, Jalaja, additional, Harb, Jason, additional, and How, Jonathan, additional

Published
2022
Full Text
View/download PDF

4. Preliminary Results of an Ongoing Phase 1 Dose Escalation Study of the Novel Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with B-Cell Non-Hodgkin Lymphoma

Author

Shah, Nirav N., primary, Mattour, Ahmad H., additional, Popplewell, Leslie L., additional, Andreadis, Charalambos, additional, Melear, Jason M., additional, Spira, Alexander I., additional, Shulman, Jonah, additional, Manda, Sudhir, additional, Burke, John M., additional, Chhabra, Saurabh, additional, Sharman, Jeff P, additional, Krishnan, Amrita, additional, Shah, Nina, additional, DiLea, Clifford, additional, Kuriakose, Jason, additional, Berman, Craig Jerome, additional, Matheny, Shannon L., additional, Leonard, John P., additional, and Molina, Arturo, additional

Published
2020
Full Text
View/download PDF

5. Preliminary Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors

Author

Shastri, Aditi, Feldman, Eric J, Starodub, Alexander N, Feldman, Tatyana, Rodriguez, Cristina P, Epstein-Peterson, Zachary D., Stevens, Don A., Olszewski, Adam J, Huen, Auris O, Porcu, Pierluigi, Reneau, John C, Barta, Stefan K., Marchi, Enrica, Mattour, Ahmad H, Pinter-Brown, Lauren C., Perea, Rachelle, Donohue, Sean, Dey, Joyoti, Agarwal, Sagar, Karnik, Rahul, Gollerkeri, Ashwin, Gollob, Jared, and Smith, Stephen D

Abstract

Background:KT-333is a first-in-class, potent, highly selective, heterobifunctional small molecule degrader of the signal transducer and activator of transcription 3 (STAT3) protein. Aberrant activation of STAT3 resulting from activating mutations or deregulated cytokine signaling underlies various malignancies including peripheral T-cell lymphomas (PTCL), cutaneous T-cell lymphoma (CTCL), and large granular lymphocytic leukemia (LGL-L). Approximately 70% of human cancers including hematological malignancies and solid tumors exhibit increased levels of phosphorylated STAT3 (pSTAT3), a biomarker of pathway activation. In non-clinical studies, treatment with KT-333 resulted in durable tumor regressions with weekly (QW) or once every two weeks IV administration in STAT3-dependent T cell lymphomas. STAT3 degradation also sensitized immunocompetent mouse models of solid and liquid cancers to anti-PD1(ASH 2021, SITC 2021).

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results